News|Articles|July 31, 2025

Psychotherapy: July Special Report Recap

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Subscribe

Related Content

Restoring Emotional Self-Awareness After Brain Injury: Research Explores Novel Approach

ByDawn Neumann, PhD, FACRM

July 24th 2026

Addressing Sexual Wellness: A Psychiatric Perspective

ByGrace L. Johnson, MD,Alex Rains, MD,Renee Sorrentino, MD

June 11th 2026

Psychotherapy and the Prevention of Relapse in Schizophrenia

ByMark L. Ruffalo, MSW, DPsa,Trisha M. Ruffalo, MSW

May 21st 2026

Advances in Ketamine-Assisted Psychotherapy

ByFernando Espí Forcén, MD, PhD

May 19th 2026

Podcast: The Intersection of Psychotherapy and Psychopharmacology for Mood Disorders. Optimizing Patient Outcomes With Holly A. Swartz, MD

ByJoseph F. Goldberg, MD,Holly A. Swartz, MD

May 1st 2026

Latest CME

Video

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Video

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

John Koo, MD; T.J. Chao, MPAS, PA-C

Video

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Ilan Melnick, MD; Linda Collado, MD, DABPN, FAPA; Maria Collado, MD, FAPA

Video

Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Patricia Junquera, MD; Maria Collado, MD; Erin C. Crown, MHSPAS, PA-C, Psych-CAQ

Video

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Juan D. Oms, MD, FAPA; Linda Collado, MD, DABPN, FAPA; Ginger Shupe, MD

Video

(CPE Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Video

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Psychotherapy: July Special Report Recap

Related Content

Restoring Emotional Self-Awareness After Brain Injury: Research Explores Novel Approach

Addressing Sexual Wellness: A Psychiatric Perspective

Psychotherapy and the Prevention of Relapse in Schizophrenia

Advances in Ketamine-Assisted Psychotherapy

Podcast: The Intersection of Psychotherapy and Psychopharmacology for Mood Disorders. Optimizing Patient Outcomes With Holly A. Swartz, MD

Latest CME

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

(CPE Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Trending on Psychiatric Times

Making Sense of the New Alzheimer Treatment Landscape, With Aaron Ritter, MD

Real-World and Long-Term Trial Data Show Xanomeline/Trospium Cuts Hospitalizations, Antipsychotic Burden in Schizophrenia

What's New in Psychiatric Treatment? Highlights From the 2026 Southern California Psychiatry Conference

A New Mechanism for ADHD: Raman Baweja, MD, on Centanafadine's FDA Approval

PET Imaging Confirms Lower Muscarinic M1 Receptor Availability in Schizophrenia